2018;71:e13 115. S2.2-38. Pender A, Lloyd-Jones DM, Stone NJ, et al. Refining statin prescrib- ing in lower-risk individuals: informing risk/benefit decisions. J Am Coll Cardiol. 2016;68:1690 7. S2.2-39. Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the commu- nity: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. S2.2-40. Kavousi M, Leening MJG, Nanchen D, et al. Comparison of applica- tion of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular dis- ease prevention in a European cohort. JAMA. 2014;311:1416 23. S2.2-41. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk predic- tion equations in 400000 primary care patients in New Zealand: a derivation and validation study. Lancet. 2018;391:1897 907. S2.2-42. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association- American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598 608. S2.2-43. Emdin CA, Khera AV, Natarajan P, et al. Evaluation of the pooled cohort equations for prediction of cardiovascular risk in a contempo- rary prospective cohort. Am J Cardiol. 2017;119:881 5. S2.2-44. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atheroscle- rotic cardiovascular risk equation in a large contemporary, multieth- nic population. J Am Coll Cardiol. 2016;67:2118 30. S2.2-45. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underas- certainment in the Women s Health Study. JAMA Intern Med. 2014;174:1964 71. S2.2-46. Sussman JB, Wiitala WL, Zawistowski M, et al. 